此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

来自相关或无关供体的 Alpha/Beta T 细胞耗尽造血干细胞移植治疗儿童和青年血液病

2026年10月28日 更新者:University of Wisconsin, Madison

TCRαβ+ 和 CD19+ 耗尽的造血干细胞移植,来自密切匹配的无关供体或单倍体相关供体,用于治疗儿童和年轻人的血液病

This study is being done to see if the investigators can take peripheral blood stem cells from either an adult family member or a closely matched unrelated donor, and run them through a special lab instrument to remove alpha/beta T cells and B cells and then give them to the patient to treat disease. This is an experimental way of doing a hematopoietic stem cell transplant (HSCT). The investigators want to see if the new stem cells will grow without bad graft vs. host disease (GVHD). This treatment approach is experimental in the United States.

研究概览

详细说明

This single institution, phase I clinical trial will determine the safety and feasibility of employing T-cell receptor (TCR) αβ+ and CD19+ (Cluster of Differentiation) depleted hematopoietic stem cell transplantation (HSCT) using peripheral blood stem cells (PBMC) from closely matched unrelated donors or haploidentical donors to treat non-malignant hematologic diseases in children and young adults. Allogeneic hematopoietic stem cell transplantation has become a curative option for children and adolescents with a variety of otherwise fatal conditions. To reduce the incidence and severity of graft-versus-host disease (GVHD) associated with allogeneic hematopoietic stem cell transplantation, donor grafts are depleted of T cells, either using CD34+ selection or CD3+/CD19+ depletion of grafts. However, these selection processes also deplete the graft of protective cell subsets, such as γδ T cells, natural killer (NK) cells, monocytes and dendritic cells, which play important roles in the immune response to infectious agents. Moreover, the presence of NK cells and γδ T cells in donor grafts is associated with more rapid immune reconstitution after HSCT transplantation. In order to retain these protective immune cell subsets, this trial will use a novel, highly selective graft engineering process using the Miltenyi CliniMACS system that selectively depletes αβ-T cells and B cells that are responsible for GVHD and Epstein Barr Virus (EBV)-related post-transplantation lymphoproliferative disorder, respectively. Prior to transplantation, patients will be treated with a conditioning regimen, specific for the original disorder.

The primary objective of this study is evaluation of the safety and feasibility of HSCT using TCRαβ+/CD19+ depleted hematopoietic stem cells to treat non-malignant hematologic diseases. This will be assessed by evaluating the incidence of graft failure, grade III-IV acute GVHD and chronic GVHD and TRM.

Secondary objectives include the evaluation of immune reconstitution and incidence of post-transplant infections, adverse events, serious adverse events, overall and disease-free survival and the efficiency of graft processing by the CliniMACS System.

研究类型

介入性

注册 (估计的)

12

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Celeste Matsushima
  • 电话号码:608-890-8069

研究联系人备份

学习地点

    • Wisconsin
      • Madison、Wisconsin、美国、53792
        • 招聘中
        • American Family Children's Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

3个月 至 25年 (孩子、成人)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • No Human leukocyte antigen (HLA) identical sibling available AND

  • NO HLA matched unrelated donor available OR urgent need of HSCT precludes time necessary to search for suitable HLA matched unrelated donor AND

  • Haploidentical donor OR closely matched unrelated donor available and willing to undergo mobilization and apheresis

  • If subject has genetically confirmed inherited bone marrow failure, related donor must be evaluated for this disorder and testing must be negative.

  • If subject has sickle cell disease, donor must be unaffected or have only sickle cell trait

  • Patient must be diagnosed with one of the following diseases or disorders:

    • Hemoglobinopathies

      • Sickle Cell Disease for patients ≤ 21 years of age for whom hydroxyurea has been trialed for at least six months, and failed
      • Thalassemia Major for patients ≤ 21 years of age
    • Acquired Bone Marrow Failure Syndromes

      • Paroxysmal Nocturnal Hemoglobinuria with bone marrow failure
      • Myelodysplastic Syndromes (lower risk)
      • Severe acquired aplastic anemia
    • Inherited Bone Marrow Failure Syndromes

      • Fanconi Anemia
      • Diamond Blackfan Anemia
      • Dyskeratosis Congenita and related telomere disorders
      • Congenital Thrombocytopenia Syndromes
      • Severe Congenital Neutropenia
      • Shwachman-Diamond Syndrome
    • Inborn Errors of Immunity (IEI) or Primary Immune Regulatory Disorders (PIRD)

      • Wiskott-Aldrich syndrome (WAS)
      • Chronic granulomatous disease (CGD)
      • Severe combined immunodeficiency (SCID)
      • Primary hemophagocytic lymphohistiocytosis (HLH)
  • Age ≤ 25 years (except patients with hemoglobinopathies)

  • Life Expectancy ≥ 3 months

  • Karnofsky (patients > 16 years)/Lansky (patients ≤ 16 years) index ≥ 60

  • Organ Function Requirements

    • Renal Function

      • Creatinine clearance or radioisotope Glomerular Filtration Rate (GFR) greater than or equal to 60 ml/min/1.73m^2
    • Liver Function

      • Total bilirubin < 3 mg/dL
      • Alanine aminotransferase (ALT)/ Serum glutamic-pyruvic transaminase; synonymous with ALT (SCPT) ≤ 3 x Upper Limit of Normal (ULN) for age
    • Cardiac Function

      • Ejection fraction of > 40% by Multiple gated acquisition scan (MUGA) or echocardiogram
    • Pulmonary Function

      • No evidence of dyspnea at rest
      • No supplemental oxygen requirement
      • If measured, carbon monoxide diffusion capacity (DLCO) > 50%
  • Willing to use effective birth control method if patient is of reproductive potential

  • Informed consent obtained (patient or legal representative)

Exclusion Criteria:

  • Pregnant
  • HIV infection
  • Uncontrolled, serious active infection at screening
  • Significant serious intercurrent illnesses
  • Enrollment in any other treatment study that would interfere with the endpoints of this study according to judgement of Principal Investigator (or PI designee).

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Treatment arm

Participants will undergo a conditioning regimen, specific for the original disease, After that peripheral blood stem cell transplant from a haploidentical donor or closely matched unrelated donor, depleted of TCRαβ+ and CD19+ cells using the CliniMACS TCR α/β-biotin and CD19 Systems will be administered intravenously on Day 0 to all participants.

After undergoing a disease specific conditioning regimen (standard of care), participants will receive peripheral blood stem cell transplant from a haploidentical donor or closely matched unrelated donor, depleted of TCR αβ+ and CD19+ cells using the CliniMACS TCR α/β-biotin and CD19 Systems.

The CliniMACS Cell Selection System is based on magnetic-activated cell sorting mechanism. The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Incidence of grade III-IV acute graft-versus-host disease (GVHD)
大体时间:100 days post transplantation

Acute GVHD will be assessed and graded according to the Keystone Consensus Criteria for staging and grading of acute graft-versus-host disease.

100 days post transplantation
Incidence of extensive chronic GVHD
大体时间:up to 2 years

Chronic GVHD will be assessed according to the current CIBMTR (Center for International Blood and Marrow Transplant Research) manual reflecting a grading system published by Sullivan KM (Sullivan 1981).

up to 2 years
Incidence of graft failure
大体时间:up to 2 years after graft

Graft failure - defined as failure to achieve ANC > 500 /µL at Day +28 or initial neutrophil engraftment followed by a decline in ANC < 500 /µL that is unresponsive to growth factor therapy (secondary graft failure).

up to 2 years after graft
Incidence of Treatment Related Mortality (TRM)
大体时间:Day +100 post-HSCT

TRM - defined as death from any cause other than disease progression.

Day +100 post-HSCT

次要结果测量

结果测量
措施说明
大体时间
总生存期(OS)
大体时间:长达 2 年
长达 2 年
CliniMACS 系统效率:TCRαβ+ 和 CD19+ 耗尽程序后恢复的活 CD34+ 细胞百分比
大体时间:HSCT 后长达 12 个月
HSCT 后长达 12 个月
GVHD 发病率与供体杀伤细胞免疫球蛋白样受体 (KIR) 单倍型含量的相关性
大体时间:长达 2 年
长达 2 年
GVHD 发病率与供体和受体之间的杀伤细胞免疫球蛋白样受体 (KIR)/KIR 配体错配之间的相关性。
大体时间:长达 2 年
长达 2 年
发生与输注 HSC 移植物相关的不良事件的参与者人数
大体时间:第 0 天
第 0 天
严重不良事件的发生率
大体时间:长达 2 年
长达 2 年
CliniMACS system efficiency: log depletion value for CD19/CD20+ B cells after the TCRαβ+ and CD19+ depletion procedure
大体时间:Day 0
Day 0
CliniMACS system efficiency: log depletion value of TCRαβ+ T cells after the TCRαβ+ and CD19+ depletion procedure
大体时间:Day 0
Day 0
Time to neutrophil engraftment
大体时间:up to 28 days following HSCT

The time to neutrophil engraftment is defined as the post-transplant day that is the first of 3 consecutive days with an absolute neutrophil count (ANC) of >500/µL as assessed by CBC.

up to 28 days following HSCT
Time to platelet engraftment
大体时间:up to 28 days following HSCT

The time to platelet engraftment is defined as the post-transplant day that is the first of 3 consecutive days with a platelet count ≥ 20,000/µL as assessed by complete blood count (CBC), without platelet support (transfusion) for 7 days.

up to 28 days following HSCT
Percentage donor chimerism using Short Tandem Repeat (STR)
大体时间:up to 12 months following HSCT

Short tandem repeat (STR) analysis will provide the percentage donor chimerism at specific time points post-transplant.

up to 12 months following HSCT
Kinetics of lymphocyte reconstitution via immunophenotyping using flow cytometry
大体时间:up to 12 months following HSCT

Lymphocyte reconstitution will be assessed at specific time points post-HSCT, expressed as the percentage of white blood cells comprised of T, B and NK cell subsets.

up to 12 months following HSCT
CliniMACS system efficiency: number of viable blood cell subsets after the TCRαβ+ and CD19+ depletion procedure
大体时间:Day 0

Number of viable CD34+ blood stem cells, CD20+ B cells, CD3-CD56+ NK cells, TCRαβ+ T cells, and TCRγδ+ T cells in the HSC graft after the TCRαβ+ and CD19+ depletion procedure

Day 0
Event free survival
大体时间:up to 1 years

An event is defined as death, graft failure or stable mixed chimerism with disease recurrence.

up to 1 years
Incidence of symptomatic bacterial/fungal and viral reactivation requiring therapy
大体时间:up to 1 year

The incidence of infections (symptomatic bacterial/fungal and viral reactivation requiring therapy) will be used as an additional safety measure

up to 1 year

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Christian Capitini, MD、University of Wisconsin, Madison
  • 研究主任:Jacques Galipeau, MD、University of Wisconsin, Madison

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年11月1日

初级完成 (估计的)

2029年6月1日

研究完成 (估计的)

2030年6月1日

研究注册日期

首次提交

2021年3月2日

首先提交符合 QC 标准的

2021年3月16日

首次发布 (实际的)

2021年3月19日

研究记录更新

最后更新发布 (实际的)

2026年10月29日

上次提交的符合 QC 标准的更新

2026年10月28日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • 2020-1251
  • A536755 (其他标识符:UW Madison)
  • UW19113 (其他标识符:OnCore ID)
  • 2020-1251 (其他标识符:HS IRB UW Madison)
  • NCI-2021-02128 (注册表标识符:NCI CTRP)
  • Protocol Version 6 (其他标识符:HS-IRB UW Madison)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

The Principal Investigator, Sponsor and funding institutions (if applicable) will ensure that all mechanisms used to share data include proper plans and safeguards to protect the rights and privacy of participants who participate in this research.

IPD 共享支持信息类型

  • 研究方案
  • 树液

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅